Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $57.60

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been assigned an average recommendation of "Buy" from the eleven brokerages that are covering the company, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $58.20.

MIRM has been the subject of a number of recent research reports. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday.

Mirum Pharmaceuticals Stock Performance

MIRM traded down $1.74 on Friday, reaching $45.83. The stock had a trading volume of 335,348 shares, compared to its average volume of 533,681. The company has a market cap of $2.25 billion, a P/E ratio of -22.79 and a beta of 0.96. The business's 50-day moving average price is $46.96 and its two-hundred day moving average price is $43.40. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $54.23.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analysts' expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Sell-side analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 2,627 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares in the company, valued at approximately $1,300,059.42. The trade was a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 7,489 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the sale, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. raised its position in Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after buying an additional 312 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after acquiring an additional 318 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 2.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company's stock worth $711,000 after purchasing an additional 487 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $35,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.